Near future
Contact us
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
June 24 2022

Coronavirus / Russia-Ukraine

Near future

News to understand, anticipate, improve the future.

No Result
View All Result

News to understand, anticipate, improve the future.

Read in:  Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

The drug that blocks glutamine slows down the tumor

By hitting glutamine, the team was able to slow down the tumor and alter the metabolism of the tumor microenvironment, "awakening" the immune system.

Gianluca Ricciodi Gianluca Riccio
in Medicine
Share87Pin12Tweet35SendShare10ShareShare7
slow down the tumor

Jonathan Powell and Barbara Slusher of Johns Hopkins Medicine with a sample of the compound

November 9, 2019
⚪ Reads in 3 minutes
A A

A research team from the Johns Hopkins Cancer Center has developed a critically important compound. It blocks the metabolism of glutamine, an amino acid involved in digestive processes, slows tumor growth, and alters the tumor microenvironment. Not only that: it promotes the production of resistant and highly active anticancer T cells.

"In theory, this tumor-slowing compound can be used in various types of neoplasia," says Jonathan Powell, at the head of the study published online on 7 November on Science.

By targeting glutamine metabolism, we were not only able to inhibit tumor growth and change the tumor microenvironment, but also to alter T-cells in a way that greatly improved cancer immunotherapy.

Jonathan Powell, associate director of Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Kimmel Cancer Center

Although glutamine metabolism is a component of all cells in the body, the DON drug selectively targets cancer cells because they are the "hungriest" for glutamine, Powell said. 

"What is emerging in metabolic therapy (this is why it is so important) is that a treatment like ours becomes selective because it preferably affects the cells that have the greatest demand."

Maybe you are also interested

Rectal cancer, new drug eliminates it without chemo or surgery

Protein destroys difficult tumors: it can lead to a "universal" cure

Vaxinia, first patient receives oncolytic virus that kills cancer

A 'ketogenic' molecule hinders colorectal cancer

Powell and colleagues tested the drug, nicknamed DON JHU083, in laboratory sessions on mice with colon cancer, lymphoma and melanoma.

JHU083: the results of an aspiring cancer killer.

"At the beginning our thought was that if we had addressed the metabolism of the tumor we would have achieved two objectives: slow down tumor growth and alter the tumor microenvironment", he claims Powell. 

The tumor microenvironment (i.e. the cells, blood vessels and nutrients found in tissues adjacent to tumors) is very hostile to the immune response. It is usually acidic, hypoxic and nutrient-depleted. Basically it is an "immune system" that defends cancer ... from the cure.

In mice, treatment with JHU083 led to a significant reduction in tumor growth and improved survival in many types of cancer. The metabolism of cancer cells is literally derailed. Its effects on the tumor microenvironment are devastating. In some mice, treatment with JHU083 alone led to lasting cures. 

Easier to heal, more difficult to get sick again

These cures were facilitated because metabolic therapy triggered the natural antitumor immune response. When the researchers replenished these cancer-free mice with new tumors, they found that nearly all of them rejected the new tumor. This suggests that the JHU083 treatment had produced a powerful immune memory to recognize and attack the new tumor.

The group also showed that treating the tumors with JHU083 improved the efficacy of adoptive cell therapy. It is a type of immunotherapy in which immune T cells are collected and grown in large numbers in the laboratory before being administered to patients to increase the immune response against cancer. 

Potentially, tumors that develop metabolic pathways to avoid the impacts of JHU083 could find themselves in a "dead end," Powell said. "By adding an additional metabolic antagonist, you could potentially eliminate even resistant tumors."

tags: cancerglutamineMetabolismtumor
Previous post

Doctors announce the success of the first, er, penis transplant

Next Post

Pharmaceutical company announces: we have HIV and AIDS cure

COLLABORATE

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff
  • millirobot

    Dawn of the Millirobot Planet: Here are 6 truly incredible ones

    1987 Shares
    Share 794 Tweet 497
  • New 3D batteries: electric vehicles over 98% charged in less than 10 minutes

    1335 Shares
    Share 534 Tweet 334
  • Solar paint: where are we?

    378 Shares
    Share 151 Tweet 94
  • Meta shows the impact of the Metaverse in its new campaign

    371 Shares
    Share 148 Tweet 93
  • A thermoelectric ink can lead us to heat-powered devices

    261 Shares
    Share 104 Tweet 65

archive

Have a look here:

street food
concepts

YATAI-E, the street food restaurant of the future "autonomous generation"

What it will be like to eat street food in the "autonomous generation", when the vehicles will take us alone while we do other things to pass ...

Read More

SCALED, dynamic brace that protects and treats injuries with mobility

Storage in the basalt

Gridscale, storage of solar and wind energy in the stones

A6CACE88 76EF 4925 88B9 384313BD510F

A New Zealand system helps predict volcanic eruptions

speed of light

Physicists take a step towards space travel beyond the speed of light

Next Post

Pharmaceutical company announces: we have HIV and AIDS cure

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Subscribe to our newsletter

Environment
Architecture
Artificial intelligence
Gadgets
concepts
Design

Staff
Archives
Advertising
Privacy Policy

Medicine
Spazio
Robotica
Work
Transportation
energia

To contact the FuturoProssimo editorial team, write to [email protected]

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

Staff
Archives
Advertising
Privacy Policy

Subscribe to our newsletter

To contact the FuturoProssimo editorial team, write to [email protected]

Categories

This work is distributed under license Creative Commons Attribution 4.0 International.
© 2021 Futuroprossimo

No Result
View All Result
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+